解整合素金属蛋白酶22通过其解整合素结构域激活整合素β1促进垂体腺瘤进展
约35%的垂体腺瘤(PA)呈侵袭性,其侵袭分子机制不明。研究通过PA转录组数据库和临床标本分析ADAM22表达,并利用过表达野生型、点突变型、缺失解整合素结构域突变型及敲低ADAM22的PA细胞系,结合增殖/侵袭实验、流式细胞术、免疫组化、免疫共沉淀、质谱、磷酸化检测及裸鼠移植瘤和大鼠催乳素瘤原位模型验证。结果显示ADAM22在PA中显著高表达,通过解整合素结构域与整合素β1(ITGB1)相互作用激活FAK/PI3K和FAK/ERK通路促进PA进展;ADAM22被PKA磷酸化并招募14-3-3延缓其降解;ITGB1靶向抑制剂(抗ITGB1)具有抗肿瘤作用,与生长抑素类似物或多巴胺激动剂联用有协同效应。结论:ADAM22在PA中上调,通过激活ITGB1信号促进PA增殖、迁移和侵袭;PKA可能通过转录后修饰水平调控ADAM22降解;ITGB1可能是PA的潜在治疗靶点。
要点
- ADAM22在垂体腺瘤中显著高表达,促进PA细胞增殖、迁移和侵袭。
- ADAM22通过解整合素结构域与ITGB1结合,激活FAK/PI3K和FAK/ERK通路。
- ITGB1靶向抑制剂与生长抑素类似物或多巴胺激动剂联用有协同抗肿瘤效应。
核心结论
- ADAM22在PA中上调,通过激活ITGB1信号促进PA增殖、迁移和侵袭;PKA可能通过转录后修饰调控ADAM22降解;ITGB1可能是PA的潜在治疗靶点。
研究设计与样本
- 利用PA转录组数据库和临床标本分析ADAM22表达,构建过表达野生型、点突变、缺失解整合素结构域突变型及敲低ADAM22的PA细胞系,并进行体外功能与机制实验。
- 采用裸鼠异种移植模型和大鼠催乳素瘤原位模型验证体外发现。
主要发现
- ADAM22在PA中显著高表达,可促进PA细胞增殖、迁移和侵袭。
- ADAM22通过其解整合素结构域与ITGB1相互作用,激活FAK/PI3K和FAK/ERK信号通路。
- ADAM22被PKA磷酸化并招募14-3-3,从而延缓其降解。
- ITGB1靶向抑制剂(抗ITGB1)具有抗肿瘤作用,与生长抑素类似物或多巴胺激动剂联用有协同效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 35% of pituitary adenoma (PA) display an aggressive profile, resulting in low surgical total resection rates, high recurrence rates, and worse prognosis. However, the molecular mechanism of PA invasion remains poorly understood. Although "a disintegrin and metalloproteinases" (ADAMs) are associated with the progression of many tumors, there are no reports on ADAM22 in PA. METHODS: PA transcriptomics databases and clinical specimens were used to analyze the expression of ADAM22. PA cell lines overexpressing wild-type ADAM22, the point mutation ADAM22, the mutated ADAM22 without disintegrin domain, and knocking down ADAM22 were generated. Cell proliferation/invasion assays, flow cytometry, immunohistochemistry, immunofluorescence, co-immunoprecipitation, mass spectrometry, Reverse transcription-quantitative real-time PCR, phos-tag SDS-PAGE, and Western blot were performed for function and mechanism research. Nude mice xenograft models and rat prolactinoma orthotopic models were used to validate in vitro findings. RESULTS: ADAM22 was significantly overexpressed in PA and could promote the proliferation, migration, and invasion of PA cells. ADAM22 interacted with integrin β1 (ITGB1) and activated FAK/PI3K and FAK/ERK signaling pathways through its disintegrin domain to promote PA progression. ADAM22 was phosphorylated by PKA and recruited 14-3-3, thereby delaying its degradation. ITGB1-targeted inhibitor (anti-itgb1) exerted antitumor effects and synergistic effects in combination with somatostatin analogs or dopamine agonists in treating PA. CONCLUSIONS: ADAM22 was upregulated in PA and was able to promote PA proliferation, migration, and invasion by activating ITGB1 signaling. PKA may regulate the degradation of ADAM22 through post-transcriptional modification levels. ITGB1 may be a potential therapeutic target for PA.
引用
- Xing B, Lei Z, Wang Z, et al. A disintegrin and metalloproteinase 22 activates integrin β1 through its disintegrin domain to promote the progression of pituitary adenoma. Neuro Oncol. 2024. PMID: 37555799. doi:10.1093/neuonc/noad148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。